The present study investigates whether early alterations of myocardial strain and blood biomarkers predict incident cardiotoxicity in patients with breast cancer during treatment with anthracyclines, ...

Trastuzumab deruxtecan-THP was associated with a statistically significant and clinically meaningful improvement in pathologic complete response rate vs standard of care. The DESTINY-Breast11 ...

Timing and Outcomes of Palliative Care Integration Into Care of Adolescents and Young Adults With Advanced Cancer The advent of next-generation antibody-drug conjugates (ADCs), particularly ...

1 After ten years, the risk of death was reduced by 17% for people treated with Perjeta® (pertuzumab), Herceptin® (trastuzumab) and chemotherapy (the Perjeta-based regimen) for a year as post-surgery ...

Department of Radiology, Mallinckrodt Institute of Radiology, Washington University School of Medicine, St. Louis, Missouri 63110, United States ...

The medicine, Trastuzumab deruxtecan, was already available for some breast and stomach cancers. It has been approved to treat more patients, specifically adults with HER2-low or HER2-ultralow ...

WILMINGTON, Del., May 07, 2025--(BUSINESS WIRE)--Positive high-level results from the DESTINY-Breast11 Phase III trial showed ENHERTU ® (fam-trastuzumab deruxtecan-nxki) followed by paclitaxel ...

The Urgency of Affordable Biologics Biologics, though revolutionary, are prohibitively expensive. A single dose of trastuzumab, a breast cancer drug, costs over Rs. 1 lakh in India, pushing families ...

Topline results from the Phase III DESTINY-Breast11 trial show that Enhertu (trastuzumab deruxtecan) followed by paclitaxel, trastuzumab, and pertuzumab significantly improves pathologic complete ...

Fam-trastuzumab deruxtecan-nxki (T-DXd; Enhertu) followed by paclitaxel, trastuzumab (Herceptin), and pertuzumab (Perjeta; THP) led to a statistically significant and clinically meaningful improvement ...

Should the Results of the New EPOC Trial Change Practice in the Management of Patients With Resectable Metastatic Colorectal Cancer Confined to the Liver? This multicenter phase II study enrolled ...